trial

Treatment of Negative Symptoms of Schizophrenia by rTMS

NCTId NCT06595654
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 124 (estimated)
Sponsored by Centre hospitalier de Ville-Evrard, France
Primary completion 2027-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
124 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2023-06-09
Primary completion
2027-09
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
repetitive Transcranial Magnetic Stimulation

Sponsors

Centre hospitalier de Ville-Evrard, FranceLead Sponsor

Investigators

1
Dominique Januel, MD, PhDPrincipal Investigator

Sites

1 total
Neuilly-sur-Marne, France

Facts & assertions

4 sourced
Enrollment
124
Phase
NA
Primary Completion Date
2027-09
Status
RECRUITING
relationships
The graph out of here
drug
repetitive Transcranial Magnetic Stimulation
drug
lead_sponsor
Centre hospitalier de Ville-Evrard, France
company
indication
Schizophrenia
indication
Negative Symptoms in Schizophrenia
indication
Schizophrenia
indication
investigator
Dominique Januel, MD, PhD
person